Lyell Wealth Management LP Has $14.81 Million Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Lyell Wealth Management LP lifted its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 10.6% during the fourth quarter, HoldingsChannel reports. The firm owned 27,900 shares of the medical research company’s stock after acquiring an additional 2,679 shares during the quarter. Thermo Fisher Scientific comprises 1.7% of Lyell Wealth Management LP’s holdings, making the stock its 14th largest holding. Lyell Wealth Management LP’s holdings in Thermo Fisher Scientific were worth $14,809,000 at the end of the most recent reporting period.

A number of other hedge funds also recently modified their holdings of the business. Raleigh Capital Management Inc. raised its position in Thermo Fisher Scientific by 49.1% in the 3rd quarter. Raleigh Capital Management Inc. now owns 82 shares of the medical research company’s stock valued at $41,000 after buying an additional 27 shares during the last quarter. Cedar Mountain Advisors LLC raised its position in Thermo Fisher Scientific by 107.0% in the 4th quarter. Cedar Mountain Advisors LLC now owns 89 shares of the medical research company’s stock valued at $47,000 after buying an additional 46 shares during the last quarter. Financial Connections Group Inc. acquired a new stake in Thermo Fisher Scientific in the 4th quarter valued at approximately $53,000. Operose Advisors LLC raised its position in Thermo Fisher Scientific by 250.0% in the 3rd quarter. Operose Advisors LLC now owns 105 shares of the medical research company’s stock valued at $53,000 after buying an additional 75 shares during the last quarter. Finally, Valley National Advisers Inc. grew its stake in Thermo Fisher Scientific by 40.5% in the third quarter. Valley National Advisers Inc. now owns 111 shares of the medical research company’s stock valued at $56,000 after purchasing an additional 32 shares in the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Insider Buying and Selling

In related news, Director Debora L. Spar sold 164 shares of the business’s stock in a transaction on Monday, February 12th. The stock was sold at an average price of $546.97, for a total transaction of $89,703.08. Following the sale, the director now owns 1,207 shares in the company, valued at approximately $660,192.79. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 14,566 shares of the company’s stock in a transaction dated Wednesday, February 7th. The stock was sold at an average price of $562.00, for a total value of $8,186,092.00. Following the sale, the senior vice president now owns 12,901 shares in the company, valued at approximately $7,250,362. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Debora L. Spar sold 164 shares of the company’s stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $546.97, for a total value of $89,703.08. Following the completion of the sale, the director now owns 1,207 shares in the company, valued at approximately $660,192.79. The disclosure for this sale can be found here. Insiders have sold 50,277 shares of company stock worth $28,513,384 in the last 90 days. Insiders own 0.32% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on TMO shares. Barclays downgraded Thermo Fisher Scientific from an “overweight” rating to an “equal weight” rating and raised their price target for the company from $475.00 to $555.00 in a research note on Wednesday, January 24th. Citigroup started coverage on Thermo Fisher Scientific in a research note on Monday, March 18th. They issued a “neutral” rating and a $620.00 price target for the company. Raymond James raised their price target on Thermo Fisher Scientific from $515.00 to $605.00 and gave the company an “outperform” rating in a research note on Thursday, February 1st. Sanford C. Bernstein reiterated a “market perform” rating on shares of Thermo Fisher Scientific in a research note on Monday, January 8th. Finally, Evercore ISI lifted their target price on Thermo Fisher Scientific from $575.00 to $610.00 and gave the stock an “outperform” rating in a research note on Thursday, April 4th. Five analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Thermo Fisher Scientific presently has an average rating of “Moderate Buy” and a consensus price target of $604.69.

Thermo Fisher Scientific Price Performance

NYSE TMO traded up $3.03 during midday trading on Wednesday, hitting $577.62. The company had a trading volume of 2,034,882 shares, compared to its average volume of 1,567,231. The company has a market capitalization of $220.48 billion, a PE ratio of 37.39, a P/E/G ratio of 2.31 and a beta of 0.80. The company has a current ratio of 1.75, a quick ratio of 1.39 and a debt-to-equity ratio of 0.67. The firm has a 50-day moving average price of $572.61 and a 200-day moving average price of $529.06. Thermo Fisher Scientific Inc. has a twelve month low of $415.60 and a twelve month high of $603.82.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, January 31st. The medical research company reported $5.67 EPS for the quarter, topping analysts’ consensus estimates of $5.64 by $0.03. Thermo Fisher Scientific had a return on equity of 18.78% and a net margin of 13.99%. The company had revenue of $10.89 billion during the quarter, compared to analysts’ expectations of $10.73 billion. During the same quarter in the previous year, the firm earned $5.40 EPS. Thermo Fisher Scientific’s revenue was down 4.9% on a year-over-year basis. As a group, analysts anticipate that Thermo Fisher Scientific Inc. will post 21.51 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, April 15th. Investors of record on Friday, March 15th were given a dividend of $0.39 per share. The ex-dividend date of this dividend was Thursday, March 14th. This represents a $1.56 dividend on an annualized basis and a yield of 0.27%. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. Thermo Fisher Scientific’s payout ratio is currently 10.10%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.